Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up

Blood

Volumn 118, Issue 4, 2011, Pages 884-893

  Cappellini, M Domenica ^a   Bejaoui, Mohamed ^b   Agaoglu, Leyla ^c   Canatan, Duran ^d   Capra, Marcello ^e   Cohen, Alan ^f   Drelichman, Guillermo ^g   Economou, Marina ^h   Fattoum, Slaheddine ⁱ   Kattamis, Antonis ^j   Kilinc, Yurdanur ^k   Perrotta, Silverio ^l   Piga, Antonio ^m   Porter, John B ⁿ   Griffel, Louis ^o   Dong, Victor ^o   Clark, Joan ^o   Aydinok, Yesim ^p  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^c ISTANBUL UNIVERSITY   (Turkey)

^d SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^e Ospedale Civile Di Vicenza   (Italy)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^h Aristotle University and Hippokration General Hospital   (Greece)

ⁱ CHILDREN S HOSPITAL   (Tunisia)

^j UNIVERSITY OF ATHENS   (Greece)

^k CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o NOVARTIS PHARMA AG   (Switzerland)

^p EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; IRON;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CARDIOPULMONARY ARREST; CHILD; CHILD GROWTH; CHOLELITHIASIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLUCOSURIA; HUMAN; HYPERSPLENISM; HYPERTRANSAMINASEMIA; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DYSFUNCTION; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEXUAL DEVELOPMENT; SIDE EFFECT; THALASSEMIA MAJOR; VOMITING;

EID: 79961008228     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-316646     Document Type: Article

References (37)

1. Rund D, Rachmilewitz E. β-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34-39. (Pubitemid 38879833)
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231. (Pubitemid 28369763)
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
5. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201. (Pubitemid 28369759)
6. De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2(suppl 2):249-255.
7. Low LC. Growth of children with beta-thalassemia major. Indian J Pediatr. 2005;72(2):159-164.
8. Roth C, Pekrun A, Bartz M, et al. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr. 1997;156(10):777-783. (Pubitemid 27438798)
9. De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr. 1988;113(4):661-669.
10. Piga A, Luzzatto L, Capalbo P, et al. High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur J Haematol. 1988;40(4):380-381.
11. Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992;14(1):48-56.
12. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
13. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
14. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508. (Pubitemid 46046309)
15. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
17. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34(3):571-590. (Pubitemid 17080631)
18. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;314:1-27.
19. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291-303.
20. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13-23.
21. Thalassaemia International Federation. Guidelines for the Cinical Management of Thalassaemia. 2nd revised ed. Nicosia, Cyprus: Thalassaemia International Federation; 2008. http://www.thalassaemia.org.cy/pdf/Guidelines- 2nd-revised-edition-EN.pdf. Accessed June 21, 2011.
22. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
23. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145(2):245-254.
24. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-1587. (Pubitemid 37022545)
25. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-2371.
26. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade) in beta-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study [abstract]. Blood. 2009;114(22):Abstract 4062.
27. Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74(2):93-100. (Pubitemid 40175311)
28. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.
29. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114(19):4009-4013.
30. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
31. St Pierre TG, Clark PR, Chua-anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci. 2005;1054:379-385. (Pubitemid 43031045)
32. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674-676.
33. Wei HY, Yang CP, Cheng CH, Lo FS. Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion. 2011;51(5):949-954.
34. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32(7):564-567.
35. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101(1):91-96. (Pubitemid 36025892)
36. Najafipour F, Aliasgarzadeh A, Aghamohamadzadeh N, et al. A cross-sectional study of metabolic and endocrine complications in betathalassemia major. Ann Saudi Med. 2008;28(5):361-366.
37. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.